Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.59 |
| ▸ | ADK | P55263 | 5/20 | 0.50 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | ADA | P00813 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453126 | 1.00 | ADORA2A (0.59) | ADORA2AADKDOT1LADORA3ADORA1 | |
| SCHEMBL14598182 | 1.00 | ADORA2A (0.59) | ADORA2AADKDOT1LADORA3ADORA1 | |
| SCHEMBL14453221 | 1.00 | ADORA2A (0.59) | ADORA2AADKDOT1LADORA3ADORA1 | |
| SCHEMBL14453150 | 0.92 | ADORA2A (0.50) | ADORA2AADKDOT1LADORA3ADORA1 | |
| SCHEMBL6531303 | 0.91 | ADORA2A (0.50) | ADORA2AADKDOT1LADORA3ADORA1 | |
| SCHEMBL5512317 | 0.91 | ADORA2A (0.60) | ADORA2AADKDOT1LADORA3ADORA1 | |
| SCHEMBL14523035 | 0.91 | ADORA2A (0.60) | ADORA2AADKDOT1LADORA3ADORA1 | |
| SCHEMBL5520162 | 0.90 | ADORA2A (0.59) | ADORA2AADKDOT1LADORA3ADORA1 | |
| SCHEMBL14523037 | 0.90 | ADORA2A (0.59) | ADORA2AADKDOT1LADORA3ADORA1 | |
| SCHEMBL4865174 | 0.89 | ADK (0.49) | ADORA2AADKDOT1LNPC1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2007084157-A2 | NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167383-A1 | NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2007-07-19 | — | — | US | disclosed |
| US-7244713-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7202223-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7157434-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7144868-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1682564-A1 | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20060079468-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050215511-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005044835-A1 | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050107312-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050090463-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090463-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885DOT1L 2129/4885 |
| US-20070167383-A1 | NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885DOT1L 2129/4885 |
| US-20050107312-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885DOT1L 2129/4885 |
| US-20060079468-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885DOT1L 2129/4885 |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | HAVCR2, NR4A3, NR2C2 | ADORA2A 738/4885ADK 2532/4885DOT1L 3820/4885 |
| US-20050215511-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885DOT1L 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.